Insider Selling: Beigene Ltd (BGNE) CMO Sells 300 Shares of Stock

Beigene Ltd (NASDAQ:BGNE) CMO Jane Huang sold 300 shares of the firm’s stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $130.12, for a total transaction of $39,036.00. Following the completion of the transaction, the chief marketing officer now owns 271,621 shares of the company’s stock, valued at $35,343,324.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Jane Huang also recently made the following trade(s):

  • On Monday, April 8th, Jane Huang sold 14,130 shares of Beigene stock. The shares were sold at an average price of $142.77, for a total transaction of $2,017,340.10.
  • On Thursday, March 7th, Jane Huang sold 71 shares of Beigene stock. The shares were sold at an average price of $140.50, for a total transaction of $9,975.50.
  • On Monday, March 11th, Jane Huang sold 2,636 shares of Beigene stock. The shares were sold at an average price of $130.28, for a total transaction of $343,418.08.

Shares of NASDAQ BGNE traded down $2.21 during mid-day trading on Thursday, hitting $127.51. The stock had a trading volume of 3,998 shares, compared to its average volume of 280,873. The company has a quick ratio of 7.47, a current ratio of 7.52 and a debt-to-equity ratio of 0.14. Beigene Ltd has a 1 year low of $105.19 and a 1 year high of $220.10. The company has a market cap of $7.84 billion, a price-to-earnings ratio of -10.44 and a beta of 1.07.

Beigene (NASDAQ:BGNE) last issued its earnings results on Thursday, May 9th. The company reported ($2.81) EPS for the quarter, topping the consensus estimate of ($3.15) by $0.34. Beigene had a negative net margin of 302.58% and a negative return on equity of 44.75%. The company had revenue of $77.83 million for the quarter, compared to the consensus estimate of $55.79 million. During the same period in the previous year, the firm earned ($2.03) earnings per share. The firm’s revenue for the quarter was up 139.2% on a year-over-year basis. Equities research analysts anticipate that Beigene Ltd will post -13.16 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in BGNE. Jennison Associates LLC boosted its holdings in shares of Beigene by 1.9% during the 4th quarter. Jennison Associates LLC now owns 4,513 shares of the company’s stock valued at $633,000 after buying an additional 86 shares in the last quarter. Nissay Asset Management Corp Japan ADV boosted its holdings in shares of Beigene by 4.8% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 2,753 shares of the company’s stock valued at $363,000 after buying an additional 127 shares in the last quarter. Comerica Bank boosted its holdings in shares of Beigene by 3.5% during the 1st quarter. Comerica Bank now owns 4,365 shares of the company’s stock valued at $638,000 after buying an additional 146 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of Beigene by 116.5% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 355 shares of the company’s stock valued at $47,000 after buying an additional 191 shares in the last quarter. Finally, Neuburgh Advisers LLC bought a new stake in shares of Beigene during the 4th quarter valued at $27,000. Institutional investors and hedge funds own 79.35% of the company’s stock.

BGNE has been the subject of several research analyst reports. BidaskClub lowered shares of Beigene from a “buy” rating to a “hold” rating in a research report on Friday, January 25th. ValuEngine lowered shares of Beigene from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 15th. Piper Jaffray Companies dropped their target price on shares of Beigene to $170.00 and set an “overweight” rating for the company in a research report on Thursday, February 28th. Maxim Group set a $170.00 price target on shares of Beigene and gave the stock a “buy” rating in a research note on Thursday, February 28th. Finally, Zacks Investment Research downgraded shares of Beigene from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 4th. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. Beigene has a consensus rating of “Buy” and a consensus target price of $182.34.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Beigene Ltd (BGNE) CMO Sells 300 Shares of Stock” was originally reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/05/23/insider-selling-beigene-ltd-bgne-cmo-sells-300-shares-of-stock.html.

Beigene Company Profile

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Featured Article: Cost of Capital Explained

Insider Buying and Selling by Quarter for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.